UPC
Income statement / Annual
Last year (2025), Universe Pharmaceuticals INC's total revenue was $17.86 M,
a decrease of 22.44% from the previous year.
In 2025, Universe Pharmaceuticals INC's net income was -$3.67 M.
See Universe Pharmaceuticals INC,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
09/30/2025 |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
| Operating Revenue |
$17.86 M |
$23.02 M |
$32.31 M |
$40.14 M |
$47.98 M |
$30.70 M |
$33.23 M |
$28.51 M |
| Cost of Revenue |
$11.56 M
|
$16.95 M
|
$21.99 M
|
$18.25 M
|
$22.66 M
|
$16.61 M
|
$19.82 M
|
$15.11 M
|
| Gross Profit |
$6.30 M
|
$6.07 M
|
$10.32 M
|
$21.89 M
|
$25.33 M
|
$14.09 M
|
$13.41 M
|
$13.41 M
|
| Gross Profit Ratio |
0.35
|
0.26
|
0.32
|
0.55
|
0.53
|
0.46
|
0.4
|
0.47
|
| Research and Development Expenses |
$671.76 K
|
$3.03 M
|
$4.86 M
|
$7.62 M
|
$5.47 M
|
$583.13 K
|
$618.44 K
|
$789.38 K
|
| General & Administrative Expenses |
$4.21 M
|
$3.19 M
|
$2.22 M
|
$2.53 M
|
$3.30 M
|
$1.24 M
|
$713.65 K
|
$704.87 K
|
| Selling & Marketing Expenses |
$3.80 M
|
$7.26 M
|
$6.78 M
|
$18.30 M
|
$2.97 M
|
$1.56 M
|
$1.58 M
|
$1.68 M
|
| Selling, General & Administrative Expenses |
$8.00 M
|
$10.44 M
|
$9.00 M
|
$21.30 M
|
$6.27 M
|
$2.80 M
|
$2.29 M
|
$2.39 M
|
| Other Expenses |
$542.97 K
|
$616.27 K
|
-$17.53 K
|
-$7.53 K
|
$0.00
|
$365.77 K
|
$445.77 K
|
$474.63 K
|
| Operating Expenses |
$9.22 M
|
$14.09 M
|
$13.84 M
|
$28.91 M
|
$11.74 M
|
$3.74 M
|
$3.36 M
|
$3.65 M
|
| Cost And Expenses |
$20.77 M
|
$31.04 M
|
$36.27 M
|
$47.16 M
|
$34.39 M
|
$20.35 M
|
$23.48 M
|
$18.86 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$232.04 K
|
$278.17 K
|
$156.79 K
|
$162.40 K
|
$101.60 K
|
$123.76 K
|
$129.27 K
|
$164.92 K
|
| Depreciation & Amortization |
$517.43 K
|
$485.73 K
|
$508.79 K
|
$533.95 K
|
$446.88 K
|
$410.08 K
|
$418.43 K
|
$452.73 K
|
| EBITDA |
-$2.92 M |
-$7.36 M |
-$3.18 M |
-$6.40 M |
$14.20 M |
$10.61 M |
$10.17 M |
$10.11 M |
| EBITDA Ratio |
-0.16
|
-0.32
|
-0.1
|
-0.16
|
0.3
|
0.35
|
0.31
|
0.35
|
| Operating Income Ratio |
-0.16
|
-0.35
|
-0.11
|
-0.17
|
0.28
|
0.33
|
0.29
|
0.34
|
| Total Other Income/Expenses Net |
-$756.14 K
|
-$100.75 K
|
-$413.77 K
|
-$545.35 K
|
$57.51 K
|
-$151.29 K
|
-$99.77 K
|
-$138.28 K
|
| Income Before Tax |
-$3.67 M
|
-$8.12 M
|
-$3.94 M
|
-$7.98 M
|
$13.65 M
|
$10.10 M
|
$9.65 M
|
$9.52 M
|
| Income Before Tax Ratio |
-0.21
|
-0.35
|
-0.12
|
-0.2
|
0.28
|
0.33
|
0.29
|
0.33
|
| Income Tax Expense |
$0.00
|
$606.70 K
|
$2.25 M
|
$752.42 K
|
$2.36 M
|
$2.54 M
|
$2.10 M
|
$1.92 M
|
| Net Income |
-$3.67 M
|
-$8.73 M
|
-$6.16 M
|
-$8.74 M
|
$11.32 M
|
$7.56 M
|
$7.55 M
|
$7.60 M
|
| Net Income Ratio |
-0.21
|
-0.38
|
-0.19
|
-0.22
|
0.24
|
0.25
|
0.23
|
0.27
|
| EPS |
-1055.75 |
-1436.12 |
-1040.53 |
-1475.02 |
2147.18 |
1295.7 |
1294.54 |
1303.36 |
| EPS Diluted |
-1055.75 |
-1436.12 |
-1040.53 |
-1475.02 |
2147.18 |
1295.7 |
1294.54 |
1303.36 |
| Weighted Average Shares Out |
$3.48 K
|
$6.08 K
|
$5.92 K
|
$5.92 K
|
$5.27 K
|
$5.83 K
|
$5.83 K
|
$5.83 K
|
| Weighted Average Shares Out Diluted |
$3.48 K
|
$6.08 K
|
$5.92 K
|
$5.92 K
|
$5.27 K
|
$5.83 K
|
$5.83 K
|
$5.83 K
|
| Link |
|
|
|
|
|
|
|
|
